This Data Coordinating Center (DCC) application is submitted in response to RFA-DK-12-014 to establish a primary glomerular disease (GDPrime) consortium with a focus on minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), immunoglobulin A nephropathy (IGAN), and idiopathic membranous nephropathy (IMN). Taken together these diseases are responsible for significant symptom burden, chronic health challenges, and progressive loss of kidney function over 1 to 20 years contributing to 10% of incident end stage kidney disease (ESRD) patients per year in the USA. Despite the health burden imposed by primary glomerular disease, significant gaps in understanding disease pathophysiology, diagnosis, monitoring, prognosis and clinical trials exists and have prevented the implementation of effective therapy for these conditions. The GDPrime consortium will establish a comprehensive research platform centered around a prospective, observational cohort study of 2400 cases and 2400 controls. The overarching goal of the DCC application is to establish the data coordinating center to provide the study design, data management and analysis expertise for the consortium and associated ancillary studies. The GDPrime DCC will establish the infrastructure for conduct of the GDPrime study;coordinate the prospective longitudinal cohort study of children and adults with primary glomerular disease and healthy controls;define disease course and investigate predictors of outcomes in patients compared with non-disease controls and their associations with disease progression. The GDPrime DCC and overall consortium will establish a comprehensive ancillary study program for extramural collaboration and partnership to advance the identification and evaluation of novel biomarkers, therapeutic targets, outcome measures and as yet undefined research proposed by the scientific community at large.
Primary glomerular disease causes significant suffering, chronic health challenges, and progressive loss of kidney function over many years contributing to 10% of new end stage kidney disease (ESRD) patients per year in the USA. Despite the health burden imposed by glomerular disease, significant gaps exist in diagnosis, monitoring, and research that supports the effective treatment of these conditions. The primary glomerular disease (GDPrime) consortium will focus on four of those diseases, minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), immunoglobulin A nephropathy (IGAN), and idiopathic membranous nephropathy (IMN). The GDPrime consortium will establish a comprehensive research program centered around a prospective, observational cohort study of 2400 cases and 2400 controls. The resources generated by this study will support a collaborative research program involving many areas of science and medicine, empower the network of scientists working with the consortium to accelerate their research based on the rich resources provided through the accumulated cohort, specimens, scientific and analytic capacity managed through the data coordinating center (DCC). Success of the GDPrime consortium will be measured by advances in disease mechanisms and therapeutic pathways, identification and validation of outcomes relevant to patients as well as clinicians, early phase testing of novel therapies and effective public-private-patient advocate partnership across disciplines.
|Mariani, Laura H; Pendergraft 3rd, William F; Kretzler, Matthias (2016) Defining Glomerular Disease in Mechanistic Terms: Implementing an Integrative Biology Approach in Nephrology. Clin J Am Soc Nephrol 11:2054-2060|
|Pendergraft 3rd, William F; Nachman, Patrick H (2015) Recent pathogenetic advances in ANCA-associated vasculitis. Presse Med 44:e223-9|
|Schober, Fernanda Payan; Pendergraft 3rd, William F (2015) Dialogue: A blissful future for lupus nephritis: harnessing repeat kidney biopsies to identify meaningful biomarkers of disease. Lupus Sci Med 2:e000083|
|Pendergraft 3rd, William F; Badhwar, Anshul K; Preston, Gloria A (2015) Autoantigen complementarity and its contributions to hallmarks of autoimmune disease. J Theor Biol 375:88-94|
|Pendergraft 3rd, William F; Means, Terry K (2015) AGS, SLE, and RNASEH2 mutations: translating insights into therapeutic advances. J Clin Invest 125:102-4|